retatrutide and blood sugar New weekly diabetes jab cuts drives double-digit weight loss in type 2 diabetes patients in major phase 3 trial, The Lancet reports The experimental GLP-1 drug 'reta'

According to the SURPASS program, which included five studies, researchers reported that a weekly dose of tirzepatide at 15 mg significantly reduced systolic blood pressure by as much as 12.6 mm Hg [97]

It remains an experimental compound, and its full safety profile is still being established through ongoing Phase 2 and Phase 3 trials

176,177 When GLP-1 binds to GLP-1R, it triggers the activation of G-proteins, leading to an increase in the intracellular second messenger cAMP

Adolescents Wegovy is approved for adolescents aged 12 and older with a BMI at or above the 95th percentile for age and sex (obesity classification)